

Acticor Biotech announces its 2022 financial agenda

Paris, France, December 16, 2021 at 06:00 pm CET– **ACTICOR BIOTECH** (ISIN: FR0014005OJ5 – ALACT), a clinical stage biopharmaceutical company, an INSERM spin-off, is developing an innovative treatment for acute thrombotic diseases, including ischemic strokes, today announces its 2022 financial agenda.

Events	Dates*
2021 Full-Year Results	March 30th 2022
2022 Half-Year Results	September 22th 2022

**Information subject to change.*

About ACTICOR BIOTECH

Acticor Biotech, a clinical stage biopharmaceutical company, a spin-off from INSERM (the French National Institute of Health and Medical Research), is developing an innovative treatment for acute thrombotic diseases, including ischemic strokes. Acticor Biotech is developing glenzocimab (ACT017), a humanized monoclonal antibody fragment (Fab). This drug candidate is directed against a new target of major interest, platelet glycoprotein VI (GPVI), and inhibits its action. This target is involved in thrombus growth but not in physiological hemostasis, and thus limits the bleeding risk associated with its inhibition.

Acticor Biotech is listed on Euronext Growth Paris since November 2021 (ISIN: FR0014005OJ5 - ALACT).

For further information, please go to www.acticor-biotech.com

Contacts

ACTICOR BIOTECH

Gilles AVENARD
CEO
gilles.avenard@acticor-biotech.com

Sophie BINAY, PhD
Deputy CEO and Scientific Director
Sophie.binay@acticor-biotech.com

NewCap

Mathilde BOHIN / Olivier BRICAUD
Investor Relations
acticor@newcap.eu
Tel.: +33 (0)1 44 71 94 95

NewCap

Annie-Florence LOYER
Media Relations
afloyer@newcap.fr
Tel.: +33 (0)1 44 71 00 12